TargeGen Advances Topical AMD Program With $40M Series D

Boggs, Jennifer
July 2007
BioWorld Today;7/16/2007, Vol. 18 Issue 136, p1
This article reports on the funding deal closed by TargeGen Inc. for the Phase II trial of its eye drop for treating age-related macular degeneration (AMD) and other back-of-the-eye diseases. Information is presented on the total amount of money raised by the firm since its founding in 2002. The goal of the company for its ocular program is discussed. According to Chief Executive Officer and co-founder Peter Ulrich, the advent of a topical agent could change the delivery of health to AMD.


Related Articles

  • TargeGen Advances AMD Program With $40M.  // Bioworld Week;7/23/2007, Vol. 15 Issue 30, p2 

    The article reports that TargeGen Inc. closed Series D financing round, which raised $40 million that will be used to fund the upcoming Phase II development of its lead program in the U.S. The company's lead program is an eye drop for treating macular degeneration and other back-of-the-eye...

  • TargeGen initiates trial of topical AMD drug.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p4 

    The article reports on the efforts by TargeGen Inc. to conduct a single-site phase I clinical trial involving TG100801, a topically applied compound for the possible treatment of age-related macular degeneration, in the U.S. This TG100801 trial was designed to suppress disease-related edema,...

  • Clinical trial under way for topical AMD therapy.  // Ophthalmology Times;1/15/2007, Vol. 32 Issue 2, p12 

    The article reports on the phase 1 clinical trial of a topical drug for the treatment of age-related macular degeneration (AMD) by TargeGen Inc. in the U.S. The study involves the testing of its small-molecule, multitargeted kinase inhibitor TG100801 as a therapy for AMD and other eye diseases....

  • Financings Roundup.  // BioWorld Today;4/10/2008, Vol. 19 Issue 70, p6 

    The article reports on a $12 million round of financing completed by Potentia Pharmaceuticals Inc. of Louisville, Kentucky. The fund will be used to complete the company's Phase I study of POT-4, a potential treatment for age-related macular degeneration, and move it into Phase II. The drug is a...

  • Isis, TargeGen Set Sights on Eye Treatments. Weeks, Katie // San Diego Business Journal;7/17/2006, Vol. 27 Issue 29, p1 

    The article reports that San Diego, California biotechnology companies, Isis Pharmaceuticals Inc. and TargeGen Inc., will test potential drugs for the treatment of age-related macular degeneration (AMD). The companies decided to go through with the test despite the U.S. Food and Drug...

  • Ophthotech Gets $30M Series B for Trials of Lucentis Add-Ons. Morrison, Trista // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p1 

    The article reports on the 30 million U.S. dollar Series B financing secured by Ophtotech Corp. The financing round is designed to support the clinical trials of the company's age-related macular degeneration (AMD) drugs. Samir Patel, president and chief executive officer (CEO) of Ophthotech,...

  • Sight preserved in AMD patients receiving steroid derivative. Charters, Lynda // Ophthalmology Times;11/1/2003, Vol. 28 Issue 31, p59 

    Reports that findings from a phase II/III study conducted by the Anecortave Acetate Clinical Study Group indicate that anecortave acetate can have a positive impact on the treatment of patients with age-related macular degeneration (AMD). Long-term benefits that anecortave acetate can provide...

  • Vascular targeting to start phase I/II trial for patients with wet AMD.  // Ophthalmology Times;8/15/2003, Vol. 28 Issue 16, p30 

    Focuses on the start of the phase I/II clinical trial of the vascular targeting agent Combretastatin A4 Prodrug for wet age-related macular degeneration (AMD). Treatment of cancer in patients with wet AMD.

  • Ophthalmology: Interpreting the Avastin-Lucentis study for persons with macular degeneration.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that the American Health Assistance Foundation is looking forward to discoveries from Comparison of AMD Treatments Trials (CATT) on age-related macular degeneration (AMD).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics